Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.22.2.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:        
Product revenue, net $ 16,043 $ 19,610 $ 55,074 $ 45,617
Other revenue 73   2,629  
Total Revenue 16,116 19,610 57,703 45,617
Operating expenses        
Cost of goods sold - product revenue 7,221 11,167 23,057 22,559
Research and development 2,812 718 6,687 747
Research and development - licenses acquired   76   13,819
Selling, general and administrative 15,575 10,755 45,481 24,776
Wire transfer fraud loss   9,540   9,540
Total operating expenses 25,608 32,256 75,225 71,441
Loss from operations (9,492) (12,646) (17,522) (25,824)
Other expense        
Interest income (3)   (10)  
Interest expense 559 1,373 1,402 2,936
Foreign exchange transaction losses 22   22  
Change in fair value of derivative liability   2   184
Total other expense 578 1,375 1,414 3,120
Loss before income taxes (10,070) (14,021) (18,936) (28,944)
Income tax (benefit) expense 10 (3,375) 50 (6,701)
Net Loss $ (10,080) $ (10,646) $ (18,986) $ (22,243)
Net loss per common share:        
Basic $ (0.57) $ (1.16) $ (1.09) $ (2.43)
Diluted $ (0.57) $ (1.16) $ (1.09) $ (2.43)
Weighted average number of common shares:        
Basic 17,618,064 9,161,333 17,464,561 9,160,344
Diluted 17,618,064 9,161,333 17,464,561 9,160,344